1. With revenue from the MS franchise declining, cost reductions and layoffs have been implemented and that always takes a toll on morale.
2. Disease area focus in shifting beyond neuroscience, which may be a good thing long-term but makes this a time of heightened uncertainty.
3. Pharma jobs are inherently unstable, even more so when major products are losing patent protection.